. 2007 Apr 17;11(2):124. doi: 10.1186/cc5731

Table 1.

Summary of outcomes from SITS-MOST, meta-analysis of previous rt-PA trials and placebo arm

	Mortality (at 3/12)	Independence (at 3/12)	Symptomatic ICH (per SITS-MOST)^a	Symptomatic ICH (per previous trials)^b
Trials	17.3%	49%	N/A	8.6%
SITS-MOST	11.3%	54.8%	1.7%	7.3%
Placebo	18.4%	30.2%	N/A	1.9%

^aBleed large enough to cause symptoms and accompanying neurological deterioration. ^bAny bleed with any alteration in neurological status, regardless of severity. rt-PA, recombinant tissue-plasminogen activator; SITS-MOST, Safe Implementation of Thrombolysis in Stroke Monitoring Study.